Hydrolysis and Transesterification of CDP323 Prodrug
161
Bourland JA, Martin DK, and Mayersohn M (1998) In vitro transesterification of cocaethylene
(ethylcocaine) in the presence of ethanol. esterase-mediated ethyl ester exchange esterase-
mediated ethyl ester exchange. Drug Metab Dispos 26:203–206.
Boyer CS and Petersen DR (1992) Enzymatic basis for the transesterification of cocaine in the
presence of ethanol: evidence for the participation of microsomal carboxylesterases. J Phar-
macol Exp Ther 260:939–946.
Liederer BM and Borchardt RT (2006) Enzymes involved in the bioconversion of ester-based
prodrugs. J Pharm Sci 95:1177–1195.
Maggs DG, Jacob R, Rife F, Lange R, Leone P, During MJ, Tamborlane WV, and Sherwin RS
(1995) Interstitial fluid concentrations of glycerol, glucose, and amino acids in human quad-
ricep muscle and adipose tissue. Evidence for significant lipolysis in skeletal muscle. J Clin
Invest 96:370–377.
Chen Z, Agrawal AK, Franklin RB, Leung KH, and Chiu SH (2004) In vitro and in vivo trans-
esterification of 1-[2(R)-(2-amino-2-methylpropionylamino)-3-(1H-indol-3-yl)propionyl]-
3(S)-benzyl-piperidine-3-carboxylic acid ethyl ester and the effects of ethanol on its phar-
macokinetics in rats. Pharm Res 21:996–999.
Coughlin JE, Pandey RK, Padmanabhan S, O’Loughlin KG, Marquis J, Green CE, Mirsalis JC,
and Iyer RP (2012) Metabolism, pharmacokinetics, tissue distribution, and stability studies of
the prodrug analog of an anti-hepatitis B dinucleoside phosphorothioate. Drug Metab Dispos
40:970–981.
Markowitz JS, DeVane CL, Boulton DW, Nahas Z, Risch SC, Diamond F, and Patrick KS (2000)
Ethylphenidate formation in human subjects after the administration of a single dose of
methylphenidate and ethanol. Drug Metab Dispos 28:620–624.
Parker RB and Laizure SC (2010) The effect of ethanol on oral cocaine pharmacokinetics reveals
an unrecognized class of ethanol-mediated drug interactions. Drug Metab Dispos 38:317–322.
Patrick KS, Straughn AB, Minhinnett RR, Yeatts SD, Herrin AE, DeVane CL, Malcolm R, Janis
GC, and Markowitz JS (2007) Influence of ethanol and gender on methylphenidate pharma-
cokinetics and pharmacodynamics. Clin Pharmacol Ther 81:346–353.
Crow JA, Herring KL, Xie S, Borazjani A, Potter PM, and Ross MK (2010) Inhibition of
carboxylesterase activity of THP1 monocytes/macrophages and recombinant human carbox-
ylesterase 1 by oxysterols and fatty acids. Biochim Biophys Acta 1801:31–41.
Dalpiaz A, Paganetto G, Pavan B, Fogagnolo M, Medici A, Beggiato S, and Perrone D (2012)
Zidovudine and ursodeoxycholic acid conjugation: design of a new prodrug potentially able to
bypass the active efflux transport systems of the central nervous system. Mol Pharm 9:
957–968.
Davenport RJ and Munday JR (2007) Alpha4-integrin antagonism—an effective approach for the
treatment of inflammatory diseases? Drug Discov Today 12:569–576.
Eng H, Niosi M, McDonald TS, Wolford A, Chen Y, Simila ST, Bauman JN, Warmus J, and Kalgutkar
AS (2010) Utility of the carboxylesterase inhibitor bis-para-nitrophenylphosphate (BNPP) in the
plasma unbound fraction determination for a hydrolytically unstable amide derivative and agonist
of the TGR5 receptor. Xenobiotica 40:369–380.
Patrick KS, Straughn AB, Reeves OT, 3rd, Bernstein H, Bell GH, Anderson ER, and Malcolm RJ
(2013) Differential influences of ethanol on early exposure to racemic methylphenidate com-
pared with dexmethylphenidate in humans. Drug Metab Dispos 41:197–205.
Pindel EV, Kedishvili NY, Abraham TL, Brzezinski MR, Zhang J, Dean RA, and Bosron WF
(1997) Purification and cloning of a broad substrate specificity human liver carboxylesterase
that catalyzes the hydrolysis of cocaine and heroin. J Biol Chem 272:14769–14775.
Satoh T and Hosokawa M (2006) Structure, function and regulation of carboxylesterases. Chem
Biol Interact 162:195–211.
Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, and La Du BN (2002) Current
progress on esterases: from molecular structure to function. Drug Metab Dispos 30:488–493.
Shi D, Yang J, Yang D, LeCluyse EL, Black C, You L, Akhlaghi F, and Yan B (2006) Anti-
influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the
activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther 319:1477–1484.
Shou M, Lin Y, Lu P, Tang C, Mei Q, Cui D, Tang W, Ngui JS, Lin CC, and Singh R, et al.
(2001) Enzyme kinetics of cytochrome P450-mediated reactions. Curr Drug Metab 2:17–36.
Sun Z, Murry DJ, Sanghani SP, Davis WI, Kedishvili NY, Zou Q, Hurley TD, and Bosron WF
(2004) Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1.
J Pharmacol Exp Ther 310:469–476.
Suzaki Y, Uemura N, Takada M, Ohyama T, Itohda A, Morimoto T, Imai H, Hamasaki H, Inano
A, and Hosokawa M, et al. (2013) The effect of carboxylesterase 1 (CES1) polymorphisms on
the pharmacokinetics of oseltamivir in humans. Eur J Clin Pharmacol 69:21–30.
Taketani M, Shii M, Ohura K, Ninomiya S, and Imai T (2007) Carboxylesterase in the liver and
small intestine of experimental animals and human. Life Sci 81:924–932.
Tang M, Mukundan M, Yang J, Charpentier N, LeCluyse EL, Black C, Yang D, Shi D, and Yan
B (2006) Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carbox-
ylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol
Exp Ther 319:1467–1476.
Hatfield MJ and Potter PM (2011) Carboxylesterase inhibitors. Expert Opin Ther Pat 21:
1159–1171.
Hosokawa M (2008) Structure and catalytic properties of carboxylesterase isozymes involved in
metabolic activation of prodrugs. Molecules 13:412–431.
Hosokawa M, Maki T, and Satoh T (1990) Characterization of molecular species of liver mi-
crosomal carboxylesterases of several animal species and humans. Arch Biochem Biophys 277:
219–227.
Hsieh PW, Hung CF, and Fang JY (2009) Current prodrug design for drug discovery. Curr
Pharm Des 15:2236–2250.
Humerickhouse R, Lohrbach K, Li L, Bosron WF, and Dolan ME (2000) Characterization of
CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res
60:1189–1192.
Imai T (2006) Human carboxylesterase isozymes: catalytic properties and rational drug design.
Drug Metab Pharmacokinet 21:173–185.
Imai T, Imoto M, Sakamoto H, and Hashimoto M (2005) Identification of esterases expressed in
Caco-2 cells and effects of their hydrolyzing activity in predicting human intestinal absorption.
Drug Metab Dispos 33:1185–1190.
Tarkiainen EK, Backman JT, Neuvonen M, Neuvonen PJ, Schwab M, and Niemi M (2012)
Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans. Clin Phar-
macol Ther 92:68–71.
Imai T, Taketani M, Shii M, Hosokawa M, and Chiba K (2006) Substrate specificity of car-
boxylesterase isozymes and their contribution to hydrolase activity in human liver and small
intestine. Drug Metab Dispos 34:1734–1741.
Wadkins RM, Hyatt JL, Wei X, Yoon KJ, Wierdl M, Edwards CC, Morton CL, Obenauer JC,
Damodaran K, and Beroza P, et al. (2005) Identification and characterization of novel benzil
(diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med
Chem 48:2906–2915.
Williams ET, Bacon JA, Bender DM, Lowinger JJ, Guo WK, Ehsani ME, Wang X, Wang H,
Qian YW, and Ruterbories KJ, et al. (2011) Characterization of the expression and activity of
carboxylesterases 1 and 2 from the beagle dog, cynomolgus monkey, and human. Drug Metab
Dispos 39:2305–2313.
Wolf C, Sidhu J, Otoul C, Morris DL, Cnops J, Taubel J, and Bennett B (2013) Pharmacody-
namic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis
subjects: a randomized, double-blind phase 1/2 study. PLoS ONE 8:e58438.
Yamaori S, Fujiyama N, Kushihara M, Funahashi T, Kimura T, Yamamoto I, Sone T, Isobe M,
Ohshima T, and Matsumura K, et al. (2006) Involvement of human blood arylesterases and
liver microsomal carboxylesterases in nafamostat hydrolysis. Drug Metab Pharmacokinet 21:
147–155.
Jana S, Mandlekar S, and Marathe P (2010) Prodrug design to improve pharmacokinetic and drug
delivery properties: challenges to the discovery scientists. Curr Med Chem 17:3874–3908.
Jewell C, Prusakiewicz JJ, Ackermann C, Payne NA, Fate G, Voorman R, and Williams FM
(2007) Hydrolysis of a series of parabens by skin microsomes and cytosol from human and
minipigs and in whole skin in short-term culture. Toxicol Appl Pharmacol 225:221–228.
Kamendulis LM, Brzezinski MR, Pindel EV, Bosron WF, and Dean RA (1996) Metabolism of
cocaine and heroin is catalyzed by the same human liver carboxylesterases. J Pharmacol Exp
Ther 279:713–717.
Koehm M, Kauert GF, and Toennes SW (2010) Influence of ethanol on the pharmacokinetics of
methylphenidate’s metabolites ritalinic acid and ethylphenidate. Arzneimittelforschung 60:
238–244.
Laizure SC, Herring V, Hu Z, Witbrodt K, and Parker RB (2013) The role of human carbox-
ylesterases in drug metabolism: have we overlooked their importance? Pharmacotherapy 33:
210–222.
Zhu HJ and Markowitz JS (2013) Carboxylesterase 1 (CES1) genetic polymorphisms and oseltamivir
activation. Eur J Clin Pharmacol 69:733–734.
Laizure SC, Mandrell T, Gades NM, and Parker RB (2003) Cocaethylene metabolism and in-
teraction with cocaine and ethanol: role of carboxylesterases. Drug Metab Dispos 31:16–20.
Lewis JP, Horenstein RB, Ryan K, O’Connell JR, Gibson Q, Mitchell BD, Tanner K, Chai S,
Bliden KP, and Tantry US, et al. (2013) The functional G143E variant of carboxylesterase 1 is
associated with increased clopidogrel active metabolite levels and greater clopidogrel response.
Pharmacogenet Genomics 23:1–8.
Address correspondence to: Dr. Hugues Chanteux, Chemin du Foriest, B-1420